A streptococcal disease was 2.7 per 100,000 population, based on data from 2001 (the most recent year for which complete data are available). Rates were highest in young children and the elderly. The rate among infants younger than one year of age was 4.8 per 100,000, while the rate among children one to four years of age was 3.6 per 100,000. Among children, the annual incidence of NF has been shown to be higher in those younger than five years of age versus those five years to younger than 16 years of age (5.9 versus 1.8 per million; P=0.0002).

Invasive group A streptococcal infection may present as a severe disease manifested by toxic shock syndrome (TSS) with or without an identifiable focus of infection. Surveillance data from Ontario suggest that 13% of cases of invasive group A streptococcal infection were streptococcal TSS and 6% were NF. Risk factors for invasive group A streptococcal disease among adults include HIV infection, cancer, heart disease, diabetes, lung disease, alcohol abuse, injection drug use and pregnancy-related risk factors. Among children, varicella is a prominent risk factor. Two studies assessing secondary cases in household contacts reported rates of 0.66 and 2.94 per 1000, respectively, which were 20 to 100 times the rates in the overall populations studied. Most secondary cases occurred within seven days of the index case. There is little information on the risk of transmission in other settings, but secondary cases appear to be rare. A secondary case associated with varicella has been reported in a child care centre. Transmission also occurs in hospitals.

Epidemiology

The most common clinical presentations of invasive group A streptococcal infections are necrotizing fasciitis (NF) or myositis, bacteremia with no septic focus and pneumonia. In Canada, the incidence of invasive group
Reporting invasive group A streptococcal infection

Currently, invasive group A streptococcal infection is reportable in all provinces and territories in Canada. Within each province or territory, procedures are in place for the rapid notification of cases to medical health officers and for timely reporting to the appropriate provincial/territorial public health official. Confirmed cases are reported at the national level.

Definitions

The Public Health Agency of Canada’s (PHAC) “Guidelines for the prevention and control of invasive group A streptococcal disease” are based on the following consensus definitions summarized below:

Confirmed case
- Laboratory confirmation of infection with or without clinical evidence of invasive disease.
- Laboratory confirmation requires the isolation of GAS (Streptococcus pyogenes) from a normally sterile site.

In the above context, clinical evidence of invasive disease includes the following:

- a. streptococcal TSS, which is characterized by hypotension (systolic blood pressure of 90 mmHg or less in adults, or less than the fifth percentile for age in children) and at least two of the following signs:
  - renal impairment (creatinine level of 177 µmol/L or greater for adults)
  - coagulopathy (platelet count of 100×10^9/L or lower, or disseminated intravascular coagulation)
  - liver function abnormality (levels of aspartate aminotransferase, alanine aminotransferase or total bilirubin two times the upper limit of normal or greater)
  - adult respiratory distress syndrome
  - generalized erythematous macular rash that may desquamate;
- b. soft-tissue necrosis, including NF, myositis or gangrene;
- c. meningitis;
- d. a combination of the above.

Severe case
- Streptococcal TSS.
- Soft-tissue necrosis (NF, myositis or gangrene).
- Meningitis.
- Group A streptococcal pneumonia. (Pneumonia with isolation of GAS from a sterile site or from bronchoalveolar lavage [BAL] fluid should be regarded as a form of invasive disease for the purposes of public health management, if no other cause for the pneumonia has been identified. Given that BAL does not provide a sterile site specimen, pneumonia with GAS isolated only from BAL fluid would not meet the national case definition and would not be nationally notifiable.)
- Other life-threatening condition(s).
- Confirmed case resulting in death.

Probable case
- Invasive disease in the absence of another identified etiology and with isolation of GAS from a non-sterile site.

Close contacts
- Household contacts who have spent at least 4 h per day on average in the previous seven days or 20 h per week with the case.
- Nonhousehold persons who share the same bed with the case or had sexual relations with the case.
- Persons who have had direct mucous membrane contact with the oral or nasal secretions of a case (eg, mouth-to-mouth resuscitation, open mouth kissing) or unprotected direct contact with an open skin lesion of the case.
- Injection drug users who have shared needles with the case.
- Selected contacts of long-term care facilities.
- Selected contacts in child care settings.
- Selected hospital contacts.
Chemoprophylaxis

Target group and prophylaxis window

With respect to the role of chemoprophylaxis, the Canadian guidelines suggest the following:

- Chemoprophylaxis should only be offered to close contacts of a confirmed case of severe GAS, and to close contacts who have been exposed to the case during the period from seven days before the onset of symptoms in the case to 24 h after the initiation of antimicrobial therapy in the case.
- Chemoprophylaxis of close contacts should be administered as soon as possible and preferably within 24 h of case identification, but chemoprophylaxis is still recommended for up to seven days after the last contact with an infectious case.
- Close contacts of all confirmed cases (ie, regardless of whether the case is a severe one) should be alerted to signs and symptoms of invasive group A streptococcal disease, and be advised to seek medical attention immediately should they develop febrile illness or any other clinical manifestations of group A streptococcal infection within 30 days of diagnosis in the index case.
- Provincial/territorial protocols for prophylaxis may vary; clinicians should become familiar with local policies.

Alternative courses of action

Variations in the approach to chemoprophylaxis exist across jurisdictions. The level of risk may vary for different groups of individuals, and there may be circumstances under which different decisions regarding chemoprophylaxis may be made. Chemoprophylaxis is not routinely recommended for contacts of cases that are not severe (eg, bacteremia or septic arthritis). These cases tend to have milder disease and so do their contacts.

Child care centres

Chemoprophylaxis is recommended for all children and staff in family or home daycare settings if the above criteria are met. Chemoprophylaxis is generally not recommended in group or institutional child care centres and preschools. However, this may be considered in specific situations such as the occurrence of more than one case of invasive group A streptococcal disease in children or staff of the child care centre within one month, or the occurrence of a concurrent varicella outbreak at the child care centre.

Choice of chemoprophylaxis agents

The first-generation cephalosporins (eg, cephalexin) are the preferred agents (Table 1). Alternative agents include second- and third-generation cephalosporins (eg, cefuroxime axetil and cefixime). Penicillin is less effective in eradicating GAS colonization than the cephalosporins. Macrolides, such as erythromycin, clarithromycin and azithromycin, may be used for chemoprophylaxis in individuals with beta-lactam allergy. However, this course of action would need to be periodically reassessed given the concern regarding macrolide-resistant GAS. Clindamycin may also be used for chemoprophylaxis in patients who are not able to tolerate beta-lactams.
### TABLE 1
Recommended chemoprophylaxis regimens for close contacts of invasive group A streptococcal disease

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-generation cephalosporins: cephalaxin, cephadroxil and cefradine</td>
<td>First-line treatment: Children and adults: 25 mg/kg to 50 mg/kg daily, to a maximum of 1 g/day in two to four divided doses for 10 days</td>
<td>Recommended drug for pregnant and lactating women. Should be used with caution in patients allergic to penicillin</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>Second-line treatment: Children: 5 mg/kg to 7.5 mg/kg every 6 h or 10 mg/kg to 15 mg/kg every 12 h (base) for 10 days (not to exceed maximum of adult dose). Adults: 500 mg every 12 h (base) for 10 days</td>
<td>Erythromycin estolate is contraindicated in persons with pre-existing liver disease or dysfunction, and during pregnancy. Sensitivity testing is recommended in areas in which macrolide resistance is unknown or known to be 10% or greater</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>Second-line treatment: Children: 15 mg/kg daily in divided doses every 12 h, to a maximum of 250 mg orally twice daily for 10 days. Adults: 250 mg orally twice daily for 10 days</td>
<td>Contraindicated in pregnancy. Sensitivity testing is recommended in areas in which macrolide resistance is unknown or known to be 10% or greater</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>Second-line treatment: Children: 8 mg/kg to 16 mg/kg daily divided into three or four equal doses for 10 days (not to exceed maximum of adult dose). Adults: 150 mg every 6 h for 10 days</td>
<td>Alternative for persons who are unable to tolerate beta-lactam antibiotics</td>
</tr>
</tbody>
</table>

Adapted from reference [1]

---

**Follow-up cultures**

Routine cultures are not required for contacts receiving antibiotic chemoprophylaxis. Cultures have no role in the identification of asymptomatic close contacts of sporadic cases occurring in the community.

**Management of severe invasive Group A Streptococcal disease**

The management of severe invasive group A streptococcal disease involves the following: supportive treatment with the use of fluid and electrolytes; specific therapy with antimicrobials; and the use of measures to minimize or neutralize the effects of toxin production, where indicated. Penicillin remains the treatment of choice [4]. The addition of clindamycin is regarded as a more effective regimen than penicillin alone, because the antimicrobial activity of clindamycin is not affected by inoculum size, has a long postantimicrobial effect and acts by inhibiting protein synthesis [4]. The latter is believed to be particularly relevant in cases of GAS in which there is no evidence of toxin-mediated disease.

Clindamycin should not be used as monotherapy because a small proportion of group A streptococci are resistant to clindamycin (1% to 2%) [4], whereas, to date, there is no resistance to penicillin.

Intravenous immune globulin may be considered in the treatment of streptococcal TSS or severe toxin-mediated disease in the absence of shock. The mechanism of action of intravenous immune globulin is unclear. Suggested regimens include 150 mg/kg to 400 mg/kg per day for five days or a single dose of 1 g/kg to 2 g/kg [4][13][14].

Other specific treatments may be required depending on the clinical situation (e.g., surgical debridement of necrotic tissue).

**Laboratory support**

The decision to engage the National Centre for Streptococcus in the investigations of clusters or outbreaks of disease due to GAS rests with the local public health agencies. Group A streptococcal strains are characterized using serological and molecular techniques. The
profile of a particular strain includes the identification of the M protein type and T protein, and anti-opacity factor testing for serum opacity-factor-positive GAS [19-19].

**Infection control for invasive Group A Streptococcal disease in health care settings**

Readers are encouraged to consult the PHAC “Guidelines for the prevention and control of invasive group A streptococcal disease” [1] as well as the related infection control guidelines [20-23]. These documents also address the prevention of noninvasive group A streptococcal disease within health care institutions.

**References**


INFECTIONIOUS DISEASES AND IMMUNIZATION COMMITTEE

Members: Robert Bortolussi MD (chair); Jane Finlay MD; Jane C McDonald MD; Heather Onyett MD; Joan L Robinson MD; Élisabeth Rousseau-Harsany MD (board representative)

Liaisons: Upton D Allen MD, Canadian Pediatric AIDS Research Group; Charles PS Hui MD, CPS Liaison to Health Canada, Committee to Advise on Tropical Medicine and Travel; Nicole Le Saux MD, Immunization Program, ACTive; Larry Pickering MD, American Academy of Pediatrics; Marina I Salvadori MD, CPS Liaison to Health Canada, National Advisory Committee on Immunization

Consultants: James Kellner MD; Noni E MacDonald MD; Dorothy L Moore MD

Principal authors: Upton D Allen MD; Dorothy L Moore MD